Selected article for: "International license and model likelihood"
Author: Andrew A. Lover
Title: Quantifying treatment effects of hydroxychloroquine and azithromycin for COVID-19: a secondary analysis of an open label non-randomized clinical trial (Gautret et al, 2020)
  • Document date: 2020_3_27
    • ID: azvbl4ie_12
    Snippet: The primary outcome was assessed using binary regressions to provide relative risks for clearance of viremia between the study arms. The main effect of interest (that of all combined HCQ-treated patients versus control), shows a marginally significant risk ratio of 3.84 (95 % CI 1.02 -14.42, p= 0.047). Analysis of the separate HCQ and HCQ+AZ outcome was not possible due to quasi-separation of the model. To address the limitations of these models,.....
    Document: The primary outcome was assessed using binary regressions to provide relative risks for clearance of viremia between the study arms. The main effect of interest (that of all combined HCQ-treated patients versus control), shows a marginally significant risk ratio of 3.84 (95 % CI 1.02 -14.42, p= 0.047). Analysis of the separate HCQ and HCQ+AZ outcome was not possible due to quasi-separation of the model. To address the limitations of these models, Firth penalized-likelihood model were used, which deal well with separation and quasi-separation. [11] 2 . CC-BY 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • binary regression and model separation: 1
    • binary regression and primary outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
    • binary regression and relative risk: 1, 2, 3, 4, 5, 6
    • binary regression and risk ratio: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
    • HCQ outcome and primary outcome: 1, 2, 3, 4, 5, 6, 7
    • HCQ outcome and relative risk: 1
    • HCQ outcome and risk ratio: 1, 2, 3
    • HCQ treat and primary outcome: 1
    • HCQ treat and risk ratio: 1
    • interest main effect and main effect: 1, 2
    • international license and model limitation: 1
    • international license and primary outcome: 1, 2
    • international license and relative risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10